Actively Recruiting

Phase 4
Age: 18Years - 50Years
FEMALE
NCT07286188

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Led by Northwestern University · Updated on 2026-04-13

40

Participants Needed

1

Research Sites

50 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this double blinded randomized control trial is to evaluate the impact of misoprostol on fluid deficit during hysteroscopic myomectomies. The main questions it aims to answer are: Is there is difference in fluid deficit in patients who receive misoprostol vs placebo pre operatively for hysteroscopic myomectomies? Participants will be randomized to received 800 mcg of either rectal misoprostol prior to their hysteroscopic myomectomy or 4 tablets of placebo (ZEEBO) prior to their hysteroscopic myomectomy.

CONDITIONS

Official Title

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Who Can Participate

Age: 18Years - 50Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients scheduled for hysteroscopic myomectomy for uterine fibroids confirmed by pelvic ultrasound or MRI within the last 12 months
  • Age 18 to 50 years
  • Uterine fibroids sized between 1 and 3 cm
  • Planned myomectomy using Myosure or resectoscope devices
  • Willing to receive rectal misoprostol or placebo before the procedure
  • Able to understand and sign informed consent
  • Acceptable medical and surgical history
  • May have been treated previously with Depo-Lupron, Depo-Provera, or oral contraceptive pills
  • May have had prior Cesarean delivery
Not Eligible

You will not qualify if you...

  • Pregnancy; negative urine pregnancy test required before surgery
  • Post-menopausal women
  • History of gynecologic cancer
  • Allergic reactions to misoprostol or similar compounds
  • Uncontrolled illnesses such as active infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social issues limiting study compliance
  • Active inflammatory bowel disease involving the rectum or other anorectal conditions interfering with safe rectal medication use

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Northwestern

Chicago, Illinois, United States, 60611

Actively Recruiting

Loading map...

Research Team

H

Hannah Pope, MD

CONTACT

J

Juan Avitia, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here